-
2008
27 November 2008: Announcement no. 3, 2008: Zealand Pharma and Helsinn Healthcare S...
-
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 1 compound in phase II, 2 c...
ZP1848
Glucagon-like Peptide-2 (GLP-2) is a peptide growth factor that specifically targets and stimulates growth of the intestinal epithelium. In experimental models of small intestinal injury and disease, administration of GLP-2 remarkably enhanced the repair, regeneration and absorptive capacity of the small intestinal mucosa. These findings aroused significant interest for the potential therapeutic use of GLP-2 in the treatment of intestinal disease and injury although the known relative instability of the peptide in the body represented a significant challenge.
ZP1848 is a SIP® modified novel GLP-2 peptide analogue with enhanced stability and efficacy. In pre-clinical pharmacological studies ZP1848 has been shown to attenuate small intestinal inflammation and enhance recovery from inflammation in an experimental model of Inflammatory Bowel Diseases (IBD).
Our objective is to develop ZP1848 as a mucosal regeneration-enhancing agent to be used for induction of remission and in the prevention of relapses in IBD patients.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.